Wells Fargo & Company Sesen Bio, Inc. Transaction History

Wells Fargo & Company

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	BUY	$0.49 - $0.61 $26 - $33	55 Added 0.51%	10,788 $6,000
Q3 2022 Nov 14, 2022	SELL	$0.0 - $0.93 $0 - $166,051	-178,550 Reduced 94.33%	10,733 $5,000
Q2 2022 Aug 12, 2022	BUY	$0.38 - $0.89 $55,057 - $128,950	144,888 Added 326.36%	189,283 $153,000
Q1 2022 May 16, 2022	SELL	$0.58 - $0.86 $37,285 - $55,285	-64,286 Reduced 59.15%	44,395 $27,000
Q4 2021 Feb 14, 2022	SELL	$0.73 - $1.28 $187,218 - $328,273	-256,464 Reduced 70.24%	108,681 $89,000
Q3 2021 Nov 15, 2021	BUY	$0.77 - $4.91 $166,718 - $1.06 Million	216,517 Added 145.68%	365,145 $289,000
Q2 2021 Aug 16, 2021	SELL	$2.18 - $4.66 $629,381 - $1.35 Million	-288,707 Reduced 66.02%	148,628 $687,000
Q1 2021 May 13, 2021	BUY	$1.3 - $3.24 $317,322 - $790,864	244,094 Added 126.32%	437,335 $1.14 Million
Q4 2020 Feb 09, 2021	BUY	$1.01 - $1.77 $193,574 - $339,234	191,658 Added 12107.26%	193,241 $260,000
Q3 2020 Nov 05, 2020	BUY	$0.67 - $1.4 $51 - $107	77 Added 5.11%	1,583 $2,000
Q2 2020 Aug 13, 2020	BUY	$0.52 - $0.87 $2 - $4	5 Added 0.33%	1,506 $1,000
Q1 2020 May 14, 2020	BUY	$0.39 - $1.03 $585 - $1,546	1,501 New	1,501 $0

Ticker SESN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 201,702,000
Market Cap $127M
Description
Sesen Bio, Inc., a late-stage clinical company, focuses on designing, engineering, developing, and commercializing targeted fusion protein therapeutics (TFPTs) for the treatment patients with cancer. Its lead product candidates include Vicineum, a locally-administered targeted fusion protein that is in Phase III clinical trials for the treatment...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.